The Business Research Company’s report on the Arteriovenous Malformations Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the arteriovenous malformations market?
The rising demand for minimally invasive procedures is expected to propel the growth of the arteriovenous malformations market going forward. Minimally invasive procedures refer to surgical or therapeutic interventions performed with small incisions or catheter-based techniques to reduce trauma, recovery time, and complications. The rising demand for minimally invasive surgeries is due to faster recovery times, as these procedures involve smaller incisions, causing less trauma to tissues and reducing healing time. This allows patients to return to their daily activities more quickly compared to traditional open surgeries, making it a preferred choice for both patients and healthcare providers. Arteriovenous malformations (AVMs) support minimally invasive procedures by allowing advanced techniques such as endovascular embolization, which uses catheters and image-guided interventions to reduce abnormal blood flow without the need for open surgery, leading to lower risks, shorter recovery times, and improved patient outcomes. For instance, in September 2023, according to the American Society of Plastic Surgeons, in 2023, a total of 25,442,640 cosmetic minimally invasive procedures were performed, representing an increase from 23,672,269 procedures in 2022. This reflects a 7% growth in minimally invasive treatments for both genders in 2023. Therefore, the rising demand for minimally invasive procedures is driving the growth of the arteriovenous malformations market.
Increasing Investment In Biotechnology Fueling The Growth Of The Market Due To Advancements In Arteriovenous Malformations Treatment And Neurovascular Innovations
The increasing investment in biotechnology is expected to propel the growth of the arteriovenous malformations market going forward. Biotechnology refers to the use of biological processes, organisms, or systems to develop products and technologies for healthcare. Increasing investments in biotechnology are due to breakthroughs in gene editing technologies such as CRISPR, which enable precise genetic modifications with innovations in medicine. Arteriovenous malformations (AVMs) contribute to biotechnology by enhancing medical imaging, gene therapy, and minimally invasive treatments, resulting in biotechnology-based solutions such as targeted drug delivery, biomaterials for vascular repair, and AI-assisted diagnostics. For instance, in August 2024, according to The BioIndustry Association (BIA), a UK-based trade association for innovative life sciences and the biotech industry, in 2024, the UK’s life sciences and biotechnology sector recorded its strongest investment quarter since the pandemic, securing $2.55 billion in the first two quarters of the year and surpassing the $2.32 billion raised in 2023. Therefore, the increasing investment in biotechnology is driving the growth of the arteriovenous malformations market.
Access Your Free Sample of the Global Arteriovenous Malformations Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21888&type=smp
How has the arteriovenous malformations market size evolved, and what are the latest forecasts for its expansion?
The arteriovenous malformations market size has grown strongly in recent years. It will grow from $2.88 billion in 2024 to $3.11 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to the increasing prevalence of arteriovenous malformations, increasing prevalence of neurological or brain disorders, rising need for better treatment for rare diseases, increasing government support for research and development, and rising business sector.
The arteriovenous malformations market size is expected to see strong growth in the next few years. It will grow to $4.13 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising usage of gene therapy, growing demand for advanced medical technology, growing demand for quality healthcare, increasing consumption of neurological drugs, and growing in step with the aging population. Major trends in the forecast period include advancements in treatment options, advancements in medical technology, advancements in microsurgical techniques, innovations in catheter technology, and advancements in minimally invasive surgeries.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21888&type=smp
Which major companies dominate the arteriovenous malformations market?
Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc., Siemens AG, Medtronic Plc, Koninklijke Philips N V, Stryker Corporation, GE Healthcare Technologies Inc, Cedars-Sinai, Penn Medicine, Terumo Corporation, Eisai Co Ltd, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc., Penumbra Inc., Max Healthcare, RWJBarnabas Health, Balt LLC, Booking Health GmbH, Duke University Health System, Shape Memory Medical Inc.
What trends will shape the future of the airport baggage conveyor system market?
Major companies operating in the arteriovenous malformations market are focusing on technological advancements, such as liquid embolic system procedural sets, to streamline treatment procedures and improve patient outcomes. The liquid embolic system procedural set refers to a pre-assembled, sterilized kit containing essential components for delivering liquid embolic agents to treat vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, launched the TRUFILL n-BCA liquid embolic system procedural set. This new set includes two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system in a single sterilized package, optimizing procedure preparation for treating cerebral arteriovenous malformations (AVMs).
Which region dominates the arteriovenous malformations market, and what factors contribute to its leadership?
North America was the largest region in the arteriovenous malformations market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report
How is the arteriovenous malformations market segmented, and which segment holds the largest share?
The arteriovenous malformations market covered in this report is segmented –
1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types
2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis
3) By Treatment: Endovascular Embolization, Neurosurgery
4) By Age Group: Adult Patients, Pediatric Patients
5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users
Subsegments:
1) By True Arteriovenous Malformation Type: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs
2) By Occult or Cryptic Type: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs
3) By Cavernous Malformations Type: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations
4) By Venous Malformation Type: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome
5) By Hemangioma Type: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas
6) By Dural Fistula Type: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula
7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21888
How is the arteriovenous malformations market defined?
Arteriovenous malformations refer to abnormal tangles of blood vessels that create direct connections between arteries and veins, bypassing the normal capillary system. This disrupts normal blood flow and oxygen circulation, potentially leading to complications. Early diagnosis and appropriate treatment are crucial to managing symptoms and reducing the risk of serious complications.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
